EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease

Carmen Arto, Elena Cristina Rusu, Helena Clavero-Mestres, Andrea Barrientos-Riosalido, Laia Bertran, Razieh Mahmoudian, Carmen Aguilar, David Riesco, Javier Ugarte Chicote, David Parada, Salomé Martínez, Fàtima Sabench und 2 weitere

European Journal of Clinical Investigation · 2024-11 · 54 (11)

DOI: 10.1111/eci.14279 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 28.06.2024. Verfasst von Carmen Arto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Servei Medicina Interna, Hospital Sant Pau i Santa Tecla de Tarragona, Tarragona, Spain. Hauptthemen laut MEDLINE: Tryptophan, Kynurenine, Obesity, Morbid, Indoleamine-Pyrrole 2,3,-Dioxygenase. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Universitat Rovira i Virgili.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The rise in obesity highlights the need for improved therapeutic strategies, particularly in addressing metabolic dysfunction‐associated steatotic liver disease (MASLD). We aim to assess the role of tryptophan metabolic pathways in the pathogenesis of obesity and in the different histological stages of MASLD. Materials and Methods We used ultra‐high performance liquid chromatography to quantify circulating levels of 15 tryptophan‐related metabolites from the kynurenine, indole and serotonin pathways. A cohort of 76 subjects was analysed, comprising 18 subjects with normal weight and 58 with morbid obesity, these last being subclassified into normal liver (NL), simple steatosis (SS) and metabolic dysfunction‐associated steatohepatitis (MASH). Then, we conducted gene expression analysis of hepatic IDO‐1 and kynyrenine‐3‐monooxygenase (KMO).

Results

Key findings in obesity revealed a distinct metabolic signature characterized by a higher concentration of different kynurenine‐related metabolites, a decrease in indole‐3‐acetic acid and indole‐3‐propionic acid, and an alteration in the serotonin pathway. Elevated tryptophan levels were associated with MASLD presence (37.659 (32.577–39.823) μM of tryptophan in NL subjects; 41.522 (38.803–45.276) μM in patients with MASLD). Overall, pathway fluxes demonstrated an induction of tryptophan catabolism via the serotonin pathway in SS subjects and into the kynurenine pathway in MASH. We found decreased IDO‐1 and KMO hepatic expression in NL compared to SS.

Conclusions

We identified a distinctive metabolic signature in obesity marked by changes in tryptophan catabolic pathways, discernible through altered metabolite profiles. We observed stage‐specific alterations in tryptophan catabolism fluxes in MASLD, highlighting the potential utility of targeting these pathways in therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TryptophanKynurenineObesity, MorbidIndoleamine-Pyrrole 2,3,-DioxygenaseHumansMaleFemaleMiddle AgedAdultIndolesObesitySerotoninFatty LiverCase-Control StudiesKynurenine 3-MonooxygenaseLiverIndoleacetic Acids

Stichwörter der Autor:innen

kynureninemetabolic dysfunction‐associated steatotic liver diseaseserotonintryptophan

Substanzen

TryptophanKynurenineIndoleamine-Pyrrole 2,3,-DioxygenaseIndolesSerotoninindoleacetic acidindolepropionic acidIDO1 protein, humanindoleKynurenine 3-Monooxygenase

Autor:innen und Institutionen

  • Servei Medicina Interna, Hospital Sant Pau i Santa Tecla de Tarragona, Tarragona, Spain.
  • Departament de Medicina i Cirurgia, Grup de Recerca GEMMAIR (AGAUR)-Medicina Aplicada (URV), Universitat Rovira i Virgili (URV), Institut d'Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain.
  • Servei Medicina Interna, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
  • Servei Anatomia Patològica, Hospital Universitari de Tarragona Joan XXIII, Tarragona, Spain.
  • Servei Anatomia Patològica, Hospital Sant Joan de Reus, Avinguda Doctor Josep Laporte, Reus, Spain.
  • Departament de Medicina i Cirurgia, Servei de Cirurgia, Hospital Sant Joan de Reus, URV, IISPV, Avinguda Doctor Josep Laporte, Reus, Spain.

ORCID-Profile: Teresa Auguet

Förderung

  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Universitat Rovira i Virgili

Zitieren

APA

Arto, C., Rusu, E. C., Clavero-Mestres, H., Barrientos-Riosalido, A., Bertran, L., Mahmoudian, R., Aguilar, C., Riesco, D., Chicote, J. U., Parada, D., Martínez, S., Sabench, F., Richart, C., & Auguet, T. (2024). Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease. European Journal of Clinical Investigation, 54(11). https://doi.org/10.1111/eci.14279

Vancouver

Arto C, Rusu EC, Clavero-Mestres H, Barrientos-Riosalido A, Bertran L, Mahmoudian R, et al. Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease. European Journal of Clinical Investigation. 2024;54(11). doi:10.1111/eci.14279

BibTeX
@article{Arto2024,
  author = {Arto, Carmen and Rusu, Elena Cristina and Clavero-Mestres, Helena and Barrientos-Riosalido, Andrea and Bertran, Laia and Mahmoudian, Razieh and Aguilar, Carmen and Riesco, David and Chicote, Javier Ugarte and Parada, David and Martínez, Salomé and Sabench, Fàtima and Richart, Cristóbal and Auguet, Teresa},
  title = {Metabolic profiling of tryptophan pathways: Implications for obesity and metabolic dysfunction‐associated steatotic liver disease},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  volume = {54},
  number = {11},
  doi = {10.1111/eci.14279}
}
Kostenlos starten →